{"filing":{"accession_number":"0001937653-26-000055","cik":"0001937653","ticker":"ZYME","company_name":"Zymeworks Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-22","primary_document":"zyme-20261022.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/zyme-20261022.htm"},"events":[{"id":37398,"run_id":34473,"accession_number":"0001937653-26-000055","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Zymeworks entered into an exclusive worldwide collaboration and license agreement with Roche for ZW209, a trispecific T cell engager, involving $55 million upfront, $40 million upon Phase 1b initiation, up to $718 million in additional milestone payments, and tiered royalties on future sales.","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42098,"accession_number":"0001937653-26-000055","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Zymeworks entered into a material definitive collaboration and license agreement with Roche granting exclusive worldwide rights to develop and commercialize ZW209. The transaction involves substantial financial terms ($55M upfront, $40M milestone, up to $718M additional milestones, plus royalties), exclusive licensing of intellectual property, and a multi-year development and commercialization partnership. This constitutes a material acquisition of rights and strategic partnership that would significantly affect investor assessment of the company's asset portfolio and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:08:08.420012+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42099,"accession_number":"0001937653-26-000055","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Zymeworks announced an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager. The deal includes a $55 million upfront payment, $40 million upon Phase 1b initiation, up to $718 million in milestone payments, and tiered royalties on future sales. This is a material strategic partnership and licensing transaction that does not fit the specific M\u0026A categories (which typically involve acquisition, disposition, or change of control) but represents a significant operational and financial milestone for the company's business strategy of partnering selected assets while advancing its R\u0026D pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:08:08.420012+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42098,"accession_number":"0001937653-26-000055","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Zymeworks entered into a material definitive collaboration and license agreement with Roche granting exclusive worldwide rights to develop and commercialize ZW209. The transaction involves substantial financial terms ($55M upfront, $40M milestone, up to $718M additional milestones, plus royalties), exclusive licensing of intellectual property, and a multi-year development and commercialization partnership. This constitutes a material acquisition of rights and strategic partnership that would significantly affect investor assessment of the company's asset portfolio and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:08:08.420012+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-10-23"},{"id":42099,"accession_number":"0001937653-26-000055","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Zymeworks announced an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager. The deal includes a $55 million upfront payment, $40 million upon Phase 1b initiation, up to $718 million in milestone payments, and tiered royalties on future sales. This is a material strategic partnership and licensing transaction that does not fit the specific M\u0026A categories (which typically involve acquisition, disposition, or change of control) but represents a significant operational and financial milestone for the company's business strategy of partnering selected assets while advancing its R\u0026D pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:08:08.420012+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-10-23"}]}